Approved,
however, Treasury is reminded to provide OMB with a summary of the
comments recieved in response to this notice of proposed rulemaking
when it becomes a final rule.
Inventory as of this Action
Requested
Previously Approved
09/30/1986
09/30/1986
09/30/1986
17,000
0
17,000
19,912
0
19,911
0
0
0
THIS REGULATION ESTABLISHES RULES TO
IMPLEMENT THE SECTION 28 CREDIT F HUMAN CLINICAL TESTING EXPENSES
FOR DRUGS FOR TREATMENT FOR RARE DISEASES OR CONDITIONS. THE TAX
CREDIT EQUALS 50 PERCENT OF THE QUALIFIED CLINICAL TESTING EXPENSES
INCURRED BY THE TAXPAYER WITH RESPECT TO THE HUMAN CLINICAL TESTING
OF SUCH DRUG.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.